-5.9%
DASH vs MRNA
+47.4%
-53.3%
-82.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.5% | -6.8% | +5.3% | -0.7% |
| 7D | -2.8% | +9.8% | -12.6% | -3.8% |
| 30D | -9.3% | +11.5% | -20.8% | -10.7% |
| 3M | -15.1% | +319.4% | -334.4% | -36.0% |
| 6M | +8.7% | +361.5% | -352.8% | -21.0% |
| YTD | -21.3% | +750.6% | -771.9% | -51.8% |
| 1Y | -12.7% | +913.0% | -925.7% | -49.2% |
| 3Y | +103.8% | +258.1% | -154.3% | +34.4% |
| 5Y | -16.8% | +9.6% | -26.4% | -26.5% |
| All | -5.9% | +47.4% | -53.3% | -40.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling